Canopus Biopharma (CBIA) Stock Statistics & Valuation Metrics

Canopus Biopharma has a market cap or net worth of $4.55K. The enterprise value is $461.13K.

Canopus Biopharma has 4,550,711,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Canopus Biopharma’s return on equity (ROE) is 57.57 and return on invested capital (ROIC) is 25400.66%.

The current PE Ratio of Canopus Biopharma is ―. Canopus Biopharma’s PEG ratio is 0.00.

In the last 12 months, Canopus Biopharma had revenue of 0.00 and earned -764.71K in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -159.18K and capital expenditures 0.00, giving a free cash flow of -159.18K billion.

Canopus Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Canopus Biopharma upcoming earnings date is ―, ―.

Canopus Biopharma as a current ratio of 0.24, with Debt / Equity ratio of -77.34%

In the past 12 months, Canopus Biopharma has paid 0.00 in taxes.

Canopus Biopharma EV to EBITDA ratio is -14.35, with an EV/FCF ratio of -1.77K.

Canopus Biopharma has $6.15K in cash and marketable securities with $183.88K in debt, giving a net cash position of -$177.73K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Canopus Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―